HOME >> BIOLOGY >> NEWS
Major grants support immunology, transplant and diabetes research at the University of Chicago

At a campus press briefing on October 6, the Juvenile Diabetes Foundation (JDF) and the National Institute of Allergy and Infectious Diseases (NIAID) announced two major, closely related, multi-year grants to research teams headquartered at the University of Chicago.

The JDF has awarded $7.5 million over a five-year period to establish the JDF Center for Islet Transplantation at the University of Chicago/University of Minnesota. The NIAID has launched a seven-year, $144-million initiative, involving nearly 40 research institutions to be known as the Collaborative Network for Clinical Research on Immune Tolerance.

Both projects will be directed by Jeffrey Bluestone, Ph.D., the Daniel K. Ludwig Professor of Pathology, Chairman of the Committee on Immunology and Director of the Ben May Institute for Cancer Research at the University of Chicago.

The JDF Center for Islet Transplantation, made possible by generous support from the McDonough Family Foundation in Chicago, will advance the use of transplants of insulin-producing pancreatic islets as a cure for diabetes. It will focus on finding new ways to prevent the body from rejecting islet transplants without causing dangerous side effects.

The Collaborative Network will concentrate on developing and testing new ways to induce immune tolerance by selectively modulating the immune system to inhibit harmful responses yet keep protective ones intact. This strategy promises to improve the success of transplants as well as treatments for autoimmune diseases such as type 1 diabetes, lupus and rheumatoid arthritis, which destroy the body's own cells.

"These are two vitally important, far-reaching and daring projects and we are pleased and honored that both will be based at the University of Chicago," said Glenn Steele, M.D., Ph.D., Dean of the Division of the Bio
'"/>

Contact: John Easton
jeaston@mcis.bsd.uchicago.edu
773-702-6241
University of Chicago Medical Center
6-Oct-1999


Page: 1 2 3 4

Related biology news :

1. Major scientific discovery in cancer research to be honored
2. Major U.S. environmental policy bears scrutiny in midlife
3. Major boost for European zebrafish research
4. Major mutations, not many small changes, might lead way to new species
5. Major new finding on genetics of Parkinsons disease zeroes in on activity of alpha synuclein
6. Major stress during pregnancy linked to autism
7. Major fossil find reveals Asian origins of salamanders
8. Major unique new study shows infrequent inspections lead to greater stream pollution
9. Major new initiative to resolve structure of protein families
10. Major air pollution study launched
11. Major grant to aid McGill University professors efforts to improve school science teaching

Post Your Comments:
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development ... for the quarter ended June 30, 2015, corporate ... and management report are available at www.sedar.com ... . "RepliCel expects to launch ...
(Date:8/28/2015)... ... ... the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake ... as the Fonz in a lab coat and Large Marge have been posted on the ... , FireflySci is proud to be the only cuvette manufacturer is the world that ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: